Published in Ann Neurol on April 17, 2013
Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia. Nat Med (2014) 2.22
Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci (2014) 1.03
Predicted overlapping microRNA regulators of acetylcholine packaging and degradation in neuroinflammation-related disorders. Front Mol Neurosci (2014) 0.96
Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer (2014) 0.96
Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Front Cell Neurosci (2014) 0.92
Myelin loss and axonal ion channel adaptations associated with gray matter neuronal hyperexcitability. J Neurosci (2015) 0.87
MicroRNA miR124 is required for the expression of homeostatic synaptic plasticity. Nat Commun (2015) 0.82
Elevated activation of CaMKIIα in the CPEB3-knockout hippocampus impairs a specific form of NMDAR-dependent synaptic depotentiation. Front Cell Neurosci (2014) 0.82
Myelin basic protein induces neuron-specific toxicity by directly damaging the neuronal plasma membrane. PLoS One (2014) 0.81
Grouping Pentylenetetrazol-Induced Epileptic Rats According to Memory Impairment and MicroRNA Expression Profiles in the Hippocampus. PLoS One (2015) 0.80
Multiple system atrophy: genetic or epigenetic? Exp Neurobiol (2014) 0.80
Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients. Acta Neuropathol Commun (2014) 0.78
Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? Acta Neuropathol Commun (2014) 0.78
Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis. Front Cell Neurosci (2015) 0.77
Decrease in levels of the evolutionarily conserved microRNA miR-124 affects oligodendrocyte numbers in Zebrafish, Danio rerio. Invert Neurosci (2015) 0.77
miRNAs As Emerging Regulators of Oligodendrocyte Development and Differentiation. Front Cell Dev Biol (2016) 0.77
Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis. Mult Scler (2013) 0.76
Chronic intermittent ethanol induced axon and myelin degeneration is attenuated by calpain inhibition. Brain Res (2015) 0.76
Molecule of the month: miRNA and Multiple Sclerosis. Bioinformation (2013) 0.76
Loss of Saltation and Presynaptic Action Potential Failure in Demyelinated Axons. Front Cell Neurosci (2017) 0.75
Is It worth Considering Circulating microRNAs in Multiple Sclerosis? Front Immunol (2016) 0.75
Cuprizone does not induce CNS demyelination in nonhuman primates. Ann Clin Transl Neurol (2014) 0.75
Meta-Analysis of Differential Connectivity in Gene Co-Expression Networks in Multiple Sclerosis. Int J Mol Sci (2016) 0.75
Role of MicroRNA in Governing Synaptic Plasticity. Neural Plast (2016) 0.75
Altered hippocampal microRNA expression profiles in neonatal rats caused by sevoflurane anesthesia: MicroRNA profiling and bioinformatics target analysis. Exp Ther Med (2016) 0.75
Spatiotemporal ablation of CXCR2 on oligodendrocyte lineage cells: Role in myelin repair. Neurol Neuroimmunol Neuroinflamm (2015) 0.75
DNA methylation in demyelinated multiple sclerosis hippocampus. Sci Rep (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
A MicroRNA feedback circuit in midbrain dopamine neurons. Science (2007) 8.33
The neuronal microRNA system. Nat Rev Neurosci (2006) 5.38
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci (2008) 5.15
Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature (2012) 4.95
Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci (2004) 4.69
MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med (2010) 4.24
Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci (2008) 3.82
Cognitive impairment in multiple sclerosis. Lancet Neurol (2008) 3.77
The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci (2008) 3.62
The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron (2006) 3.55
Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. Neuron (2010) 3.37
Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron (2009) 3.27
MicroRNA-mediated control of oligodendrocyte differentiation. Neuron (2010) 3.24
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature (2012) 3.09
Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci (2008) 2.95
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
microRNAs at the synapse. Nat Rev Neurosci (2009) 2.66
Myelination and the trophic support of long axons. Nat Rev Neurosci (2010) 2.47
MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol (2008) 2.39
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol (2009) 2.33
Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet (2008) 2.33
Regional hippocampal atrophy in multiple sclerosis. Brain (2008) 2.02
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol (2011) 1.98
MicroRNA loss enhances learning and memory in mice. J Neurosci (2010) 1.82
Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol (2003) 1.79
Natural history of multiple sclerosis. Ann Neurol (1994) 1.48
The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol (2010) 1.08
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
iCTNet: a Cytoscape plugin to produce and analyze integrative complex traits networks. BMC Bioinformatics (2011) 1.01
MicroRNAs in neural cell differentiation. Brain Res (2010) 0.97
MicroRNAs in memory processing. Neuron (2009) 0.85
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol (2007) 8.16
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci (2006) 3.85
Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci (2008) 3.82
Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med (2002) 3.68
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 3.48
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev (2009) 2.96
Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A (2009) 2.94
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol (2006) 2.93
Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J Neurosci (2002) 2.90
Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol (2003) 2.85
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet (2008) 2.83
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet (2003) 2.71
Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci (2011) 2.61
Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci (2008) 2.60
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med (2005) 2.46
Neurofascins are required to establish axonal domains for saltatory conduction. Neuron (2005) 2.41
Climbing fiber innervation of NG2-expressing glia in the mammalian cerebellum. Neuron (2005) 2.41
Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci (2009) 2.35
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin (2013) 2.18
Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology (2007) 2.10
Inducible site-specific recombination in myelinating cells. Genesis (2003) 2.07
Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med (2004) 2.02
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol (2011) 1.98
Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One (2009) 1.98
Depolarization-induced Ca2+ release in ischemic spinal cord white matter involves L-type Ca2+ channel activation of ryanodine receptors. Neuron (2003) 1.95
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
Tamoxifen-inducible glia-specific Cre mice for somatic mutagenesis in oligodendrocytes and Schwann cells. Mol Cell Neurosci (2003) 1.84
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83
Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol (2008) 1.80
The genetics of multiple sclerosis: an up-to-date review. Immunol Rev (2012) 1.74
The three SoxC proteins--Sox4, Sox11 and Sox12--exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res (2008) 1.70
Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol (2002) 1.70
Myelin regeneration: a recapitulation of development? Annu Rev Neurosci (2011) 1.70
Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain (2011) 1.63
The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat Neurosci (2009) 1.60
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J (2008) 1.60
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol (2008) 1.59
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain (2005) 1.58
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol (2010) 1.54
Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med (2007) 1.47
Seeing injectable MS therapies differently: they are more similar than different. Neurology (2009) 1.47
Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci (2012) 1.46
Glutamate stimulates oligodendrocyte progenitor migration mediated via an alphav integrin/myelin proteolipid protein complex. J Neurosci (2006) 1.45
Chronic cerebrospinal venous insufficiency: have we found the cause and cure of MS? Neurology (2011) 1.42
Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma (2015) 1.38
Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol (2011) 1.35
Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol (2007) 1.31
Production, characterization, and efficient transfection of highly pure oligodendrocyte precursor cultures from mouse embryonic neural progenitors. Glia (2008) 1.30
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A (2008) 1.27
Morphometric analysis of oligodendrocytes in the adult mouse frontal cortex. J Neurosci Res (2007) 1.26
Evolution of a neuroprotective function of central nervous system myelin. J Cell Biol (2006) 1.25
Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination. J Biol Chem (2011) 1.25
Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier. J Neurosci (2011) 1.23
Activation of necroptosis in multiple sclerosis. Cell Rep (2015) 1.21
NG2-positive cells generate A2B5-positive oligodendrocyte precursor cells. Glia (2007) 1.21
A disorganized innervation of the inner ear persists in the absence of ErbB2. Brain Res (2006) 1.21
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol (2013) 1.18
Creation of a knowledge management system for QT analyses. J Clin Pharmacol (2010) 1.18
Mammalian target of rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination. J Neurosci (2014) 1.18
N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol (2002) 1.17
Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins (2009) 1.16
Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells. Nat Neurosci (2013) 1.16
Structure and stability of internodal myelin in mouse models of hereditary neuropathy. J Neuropathol Exp Neurol (2005) 1.16
Multiple sclerosis genetics--is the glass half full, or half empty? Nat Rev Neurol (2010) 1.15
Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes. J Neurosci (2002) 1.14
Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res (2003) 1.14
Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol (2009) 1.14
Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol (2008) 1.13
Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought. J Med Internet Res (2013) 1.13
Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol (2009) 1.12
Manitoba-oculo-tricho-anal (MOTA) syndrome is caused by mutations in FREM1. J Med Genet (2011) 1.11
Inhibition of interferon-gamma signaling in oligodendroglia delays coronavirus clearance without altering demyelination. Am J Pathol (2006) 1.10
Neurogenesis in the chronic lesions of multiple sclerosis. Brain (2008) 1.10